Nirsevimab: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Nirsevimab. Educational only — not medical advice.

Labeled uses

BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season. Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Source: FDA labeling via NIH DailyMed (set 2f08fa60…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.